In addition, patients with CRCs that are microsatellite instability (MSI) and high somatic tumour mutation burden (TMB) have shown encouraging outcomes after receiving immunotherapy including one of the single-agent programmed death-ligand 1 (PD-L1) checkpoint inhibitors [6, 7]. The gene discussed is CD274; the disease is neoplasm.